BMYMP - Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
2024-05-15 19:58:10 ET
Bristol-Myers Squibb Company (BMY)
Bank of America Global Healthcare Conference 2024
May 15, 2024 2:20 PM ET
Company Participants
David Elkins – Executive Vice President and Chief Financial Officer
Conference Call Participants
Geoff Meacham – Bank of America
Chen Yang – Bank of America
Presentation
Geoff Meacham
I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David, welcome.
David Elkins
It’s good to be here. Thank you for having me.
Geoff Meacham
Yes. So let’s – we got a lot of questions, but maybe just kick it off kind of post 1Q, like the messages coming out of that, and then we’ll get right into some pipeline and portfolio questions.
David Elkins
Yes. No, thank you for that. And if you think about Bristol, we’re really writing the next chapter in the company’s history here. 150 years, this company has been around, some amazing products that we brought to the marketplace, whether you think about Abilify or Plavix in both neuroscience as well in cardiovascular. But really, what we’re focused on is delivering here and now and executing against what we have from a growth portfolio. Really excited about some of the products we have there.
We recently brought in KarXT from Karuna, which we can talk about in Q&A. But we’ve got great growth products, which I’m sure we’ll cover off, whether we’re talking about Opdualag, our cell therapy franchise, but also Camzyos in cardiovascular and Reblozyl within MDS. We’re really excited about that and continuing to grow those products. And we can talk about the growth of those in the first quarter, but also how we’re seeing it as the year progresses....
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript